Clarinex, Azomyr(desloratadine)
Aerinaze, Aerius, Azomyr, Clarinex, Dasselta, Desloratadine, Neoclarityn (desloratadine) is a small molecule pharmaceutical. Desloratadine was first approved as Azomyr on 2001-01-15. It is used to treat allergic rhinitis perennial, allergic rhinitis seasonal, and urticaria in the USA. It has been approved in Europe to treat allergic rhinitis perennial, allergic rhinitis seasonal, and urticaria. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Clarinex (generic drugs available since 2010-02-19)
CombinationsClarinex (generic drugs available since 2010-02-19, discontinued: Clarinex d)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clarinex | New Drug Application | 2022-11-14 |
| clarinex-d 12 hour | New Drug Application | 2022-06-01 |
| desloratadine | ANDA | 2024-01-19 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 2 | 5 | 11 | 1 | 19 |
| Allergic rhinitis | D065631 | — | J30.9 | — | — | 8 | 4 | — | 12 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | 2 | 7 | 3 | 12 |
| Chronic urticaria | D000080223 | — | L50.8 | — | 2 | 2 | 4 | — | 8 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 2 | 4 | 1 | 7 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | 1 | 1 | 3 | 1 | 6 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | 1 | 2 | 4 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cold temperature | D003080 | — | — | — | — | 1 | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | — | 1 | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | 1 | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | 1 | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Rhinorrhea | D000086722 | — | — | — | 1 | — | — | — | 1 |
| Peanut hypersensitivity | D021183 | EFO_0007425 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | — | — | 4 | 4 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Heat stress disorders | D018882 | — | T67.2 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Desloratadine |
| INN | desloratadine |
| Description | Desloratadine is loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. It has a role as a H1-receptor antagonist, an anti-allergic agent, a cholinergic antagonist and a drug metabolite. |
| Classification | Small molecule |
| Drug class | tricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1 |
Identifiers
| PDB | — |
| CAS-ID | 100643-71-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1172 |
| ChEBI ID | 291342 |
| PubChem CID | 124087 |
| DrugBank | DB00967 |
| UNII ID | FVF865388R (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Clarinex – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Desloratadine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Desloratadine
+
Pseudoephedrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,200 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,099 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use